Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Dermoscopy | 9 | 2020 | 346 | 3.75 | Why? |
| Alopecia Areata | 5 | 2021 | 140 | 2.19 | Why? |
| Alopecia | 4 | 2019 | 351 | 1.97 | Why? |
| Psoriasis | 8 | 2020 | 1739 | 1.70 | Why? |
| Lichen Planus | 2 | 2019 | 60 | 1.36 | Why? |
| Hair | 2 | 2018 | 175 | 1.25 | Why? |
| Hair Follicle | 3 | 2018 | 44 | 1.09 | Why? |
| Scleroderma, Systemic | 3 | 2020 | 583 | 1.09 | Why? |
| Scalp Dermatoses | 3 | 2019 | 59 | 1.06 | Why? |
| Skin Diseases | 6 | 2020 | 2509 | 0.96 | Why? |
| Skin Neoplasms | 4 | 2021 | 1679 | 0.88 | Why? |
| Finasteride | 2 | 2017 | 29 | 0.88 | Why? |
| Cyclosporins | 1 | 2020 | 16 | 0.86 | Why? |
| Lupus Vasculitis, Central Nervous System | 1 | 2019 | 7 | 0.80 | Why? |
| Eyebrows | 1 | 2018 | 14 | 0.78 | Why? |
| Eccrine Glands | 1 | 2018 | 30 | 0.78 | Why? |
| Keratins | 1 | 2018 | 33 | 0.77 | Why? |
| Bowen's Disease | 1 | 2018 | 14 | 0.74 | Why? |
| Naltrexone | 1 | 2019 | 56 | 0.74 | Why? |
| Hair Diseases | 1 | 2018 | 31 | 0.73 | Why? |
| Wool | 1 | 2017 | 2 | 0.73 | Why? |
| Protein Hydrolysates | 1 | 2017 | 15 | 0.72 | Why? |
| Adipokines | 1 | 2019 | 87 | 0.72 | Why? |
| Acitretin | 1 | 2017 | 23 | 0.72 | Why? |
| Bandages | 1 | 2018 | 109 | 0.68 | Why? |
| Isotretinoin | 1 | 2017 | 58 | 0.68 | Why? |
| Nails | 1 | 2019 | 143 | 0.67 | Why? |
| Pemphigus | 4 | 2017 | 163 | 0.66 | Why? |
| Eczema | 1 | 2020 | 227 | 0.64 | Why? |
| Diabetes Mellitus, Experimental | 1 | 2018 | 192 | 0.63 | Why? |
| Biocompatible Materials | 1 | 2018 | 214 | 0.62 | Why? |
| Scalp | 2 | 2017 | 82 | 0.62 | Why? |
| Hand Dermatoses | 1 | 2020 | 284 | 0.60 | Why? |
| Carcinoma, Basal Cell | 1 | 2018 | 144 | 0.60 | Why? |
| Skin Diseases, Vesiculobullous | 1 | 2017 | 112 | 0.59 | Why? |
| Wound Healing | 1 | 2018 | 424 | 0.54 | Why? |
| Adipose Tissue | 1 | 2019 | 612 | 0.51 | Why? |
| Janus Kinase Inhibitors | 1 | 2018 | 682 | 0.50 | Why? |
| Pigmentation Disorders | 1 | 2012 | 29 | 0.48 | Why? |
| Dysbiosis | 1 | 2018 | 685 | 0.48 | Why? |
| Dermatologic Agents | 1 | 2017 | 489 | 0.44 | Why? |
| Intestinal Mucosa | 1 | 2018 | 1046 | 0.42 | Why? |
| Dyslipidemias | 1 | 2017 | 791 | 0.42 | Why? |
| Vascular Diseases | 1 | 2019 | 846 | 0.40 | Why? |
| Cefuroxime | 1 | 2009 | 17 | 0.40 | Why? |
| Trichotillomania | 2 | 2019 | 20 | 0.37 | Why? |
| Carcinoma, Squamous Cell | 1 | 2017 | 902 | 0.37 | Why? |
| Dermatology | 5 | 2020 | 1999 | 0.35 | Why? |
| Autoimmune Diseases | 1 | 2020 | 1996 | 0.31 | Why? |
| Pregnancy Complications | 1 | 2018 | 1388 | 0.31 | Why? |
| Skin | 1 | 2018 | 2096 | 0.31 | Why? |
| Wounds and Injuries | 1 | 2018 | 1708 | 0.29 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.29 | Why? |
| Gastrointestinal Microbiome | 1 | 2018 | 1961 | 0.29 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.24 | Why? |
| Cell Survival | 2 | 2018 | 1581 | 0.24 | Why? |
| Gram-Positive Cocci | 1 | 2020 | 20 | 0.21 | Why? |
| Resistin | 1 | 2019 | 16 | 0.20 | Why? |
| Claudin-3 | 1 | 2018 | 3 | 0.20 | Why? |
| Monilethrix | 1 | 2018 | 1 | 0.20 | Why? |
| Netherton Syndrome | 1 | 2018 | 1 | 0.20 | Why? |
| Trichothiodystrophy Syndromes | 1 | 2018 | 1 | 0.20 | Why? |
| Streptozocin | 1 | 2018 | 29 | 0.19 | Why? |
| Tinea Capitis | 1 | 2018 | 5 | 0.19 | Why? |
| Humans | 42 | 2021 | 930598 | 0.19 | Why? |
| NIH 3T3 Cells | 1 | 2018 | 147 | 0.19 | Why? |
| Fatty Acid-Binding Proteins | 1 | 2018 | 93 | 0.18 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.18 | Why? |
| Ectodermal Dysplasia | 1 | 2018 | 39 | 0.18 | Why? |
| Dermatitis Herpetiformis | 1 | 2017 | 6 | 0.18 | Why? |
| Triamcinolone Acetonide | 1 | 2017 | 10 | 0.18 | Why? |
| Nephrogenic Fibrosing Dermopathy | 1 | 2017 | 7 | 0.18 | Why? |
| Scleredema Adultorum | 1 | 2017 | 6 | 0.18 | Why? |
| Sebaceous Glands | 1 | 2017 | 9 | 0.18 | Why? |
| Scleromyxedema | 1 | 2017 | 10 | 0.18 | Why? |
| Diclofenac | 1 | 2017 | 27 | 0.18 | Why? |
| Scleroderma, Localized | 1 | 2017 | 25 | 0.18 | Why? |
| Global Health | 3 | 2021 | 13911 | 0.18 | Why? |
| Adiponectin | 1 | 2019 | 123 | 0.17 | Why? |
| Vitiligo | 1 | 2018 | 76 | 0.17 | Why? |
| Permeability | 1 | 2018 | 238 | 0.17 | Why? |
| Diagnosis, Differential | 5 | 2018 | 7220 | 0.17 | Why? |
| Leptin | 1 | 2019 | 141 | 0.17 | Why? |
| Undifferentiated Connective Tissue Diseases | 1 | 2017 | 60 | 0.17 | Why? |
| Tight Junctions | 1 | 2018 | 179 | 0.17 | Why? |
| Cosmetic Techniques | 1 | 2020 | 167 | 0.17 | Why? |
| Fluorouracil | 1 | 2017 | 169 | 0.16 | Why? |
| Pruritus | 1 | 2019 | 215 | 0.16 | Why? |
| Keratinocytes | 1 | 2017 | 119 | 0.16 | Why? |
| Enterocytes | 1 | 2018 | 245 | 0.15 | Why? |
| Inflammation | 1 | 2019 | 13255 | 0.15 | Why? |
| Pemphigoid, Bullous | 1 | 2017 | 89 | 0.15 | Why? |
| Toll-Like Receptors | 1 | 2019 | 365 | 0.15 | Why? |
| Diterpenes | 1 | 2017 | 157 | 0.15 | Why? |
| Mental Disorders | 1 | 2019 | 6742 | 0.15 | Why? |
| Biomarkers | 1 | 2019 | 23361 | 0.15 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.14 | Why? |
| Dose-Response Relationship, Drug | 2 | 2019 | 3776 | 0.14 | Why? |
| Dermatologists | 1 | 2020 | 435 | 0.14 | Why? |
| Fibrosis | 1 | 2018 | 800 | 0.14 | Why? |
| Internal Medicine | 1 | 2020 | 557 | 0.14 | Why? |
| Erythema | 1 | 2018 | 400 | 0.13 | Why? |
| Fibroblasts | 1 | 2018 | 839 | 0.13 | Why? |
| Remission Induction | 1 | 2018 | 950 | 0.13 | Why? |
| Medicine | 1 | 2020 | 485 | 0.13 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.13 | Why? |
| Pneumonia, Viral | 9 | 2020 | 243684 | 0.13 | Why? |
| Coronavirus Infections | 9 | 2020 | 253789 | 0.12 | Why? |
| Signal Transduction | 2 | 2019 | 7207 | 0.11 | Why? |
| Incidence | 3 | 2019 | 25622 | 0.11 | Why? |
| Staphylococcus aureus | 1 | 2018 | 844 | 0.11 | Why? |
| Virtual Reality | 1 | 2020 | 640 | 0.11 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.11 | Why? |
| Escherichia coli | 1 | 2018 | 1547 | 0.11 | Why? |
| Dermatitis, Atopic | 1 | 2018 | 714 | 0.10 | Why? |
| Congresses as Topic | 1 | 2020 | 1347 | 0.10 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.10 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.10 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.10 | Why? |
| Hand Disinfection | 1 | 2020 | 1671 | 0.10 | Why? |
| Pandemics | 9 | 2020 | 389249 | 0.10 | Why? |
| Melanoma | 1 | 2021 | 1229 | 0.10 | Why? |
| Treatment Outcome | 4 | 2020 | 51732 | 0.10 | Why? |
| Poland | 1 | 2018 | 2368 | 0.10 | Why? |
| Immunomodulation | 1 | 2019 | 1472 | 0.10 | Why? |
| Cell Line, Tumor | 1 | 2017 | 3608 | 0.09 | Why? |
| Adult | 9 | 2021 | 244371 | 0.09 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.09 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.08 | Why? |
| Autoantibodies | 1 | 2019 | 2094 | 0.08 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.08 | Why? |
| Female | 10 | 2021 | 380317 | 0.08 | Why? |
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 40 | 0.08 | Why? |
| Antibodies, Monoclonal | 1 | 2005 | 8041 | 0.08 | Why? |
| Health Surveys | 1 | 2018 | 2841 | 0.08 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.08 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.07 | Why? |
| Self Report | 1 | 2018 | 3802 | 0.07 | Why? |
| Antibodies, Monoclonal, Murine-Derived | 1 | 2005 | 94 | 0.07 | Why? |
| Male | 9 | 2021 | 367725 | 0.07 | Why? |
| Biological Products | 1 | 2020 | 2331 | 0.07 | Why? |
| Clinical Competence | 1 | 2020 | 3263 | 0.07 | Why? |
| Artificial Intelligence | 1 | 2020 | 3543 | 0.07 | Why? |
| Etanercept | 1 | 2005 | 162 | 0.07 | Why? |
| Animals | 3 | 2019 | 78931 | 0.07 | Why? |
| Education, Medical | 1 | 2020 | 2461 | 0.06 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.06 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.06 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.06 | Why? |
| Travel | 1 | 2021 | 7220 | 0.06 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.06 | Why? |
| Adalimumab | 1 | 2005 | 389 | 0.06 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.06 | Why? |
| Child, Preschool | 2 | 2018 | 36283 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.06 | Why? |
| Infliximab | 1 | 2005 | 502 | 0.05 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.05 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.05 | Why? |
| Aged | 5 | 2018 | 215776 | 0.05 | Why? |
| Mice | 1 | 2018 | 21357 | 0.05 | Why? |
| Airports | 1 | 2021 | 284 | 0.05 | Why? |
| Injections, Intralesional | 1 | 2017 | 34 | 0.05 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.04 | Why? |
| Injections, Intradermal | 1 | 2017 | 102 | 0.04 | Why? |
| Stress, Psychological | 1 | 2021 | 10231 | 0.04 | Why? |
| Rituximab | 1 | 2005 | 1096 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2020 | 449 | 0.04 | Why? |
| Cytokines | 1 | 2019 | 15010 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Child | 2 | 2018 | 70012 | 0.04 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.04 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.03 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.03 | Why? |
| Physical Examination | 1 | 2017 | 755 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.02 | Why? |
| Smartphone | 1 | 2020 | 1840 | 0.02 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.02 | Why? |
| Aged, 80 and over | 1 | 2018 | 88759 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| Immunoglobulin G | 1 | 2005 | 21571 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2020 | 15421 | 0.01 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.01 | Why? |
Rudnicka's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(190)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(86)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_